	US 12,239,637 B2
	Compositions and methods for treating neurological disorders
Kalipada Pahan, Skokie, IL (US)
Assigned to RUSH UNIVERSITY MEDICAL CENTER, Chicago, IL (US)
Filed by Rush University Medical Center, Chicago, IL (US)
Filed on Oct. 18, 2022, as Appl. No. 17/968,264.
Application 17/968,264 is a continuation of application No. 16/958,903, granted, now 11,504,360, previously published as PCT/US2018/067888, filed on Dec. 28, 2018.
Claims priority of provisional application 62/612,899, filed on Jan. 2, 2018.
Prior Publication US 2023/0046776 A1, Feb. 16, 2023
Int. Cl. A61K 31/439 (2006.01); A61K 9/00 (2006.01); A61K 31/4178 (2006.01); A61K 31/499 (2006.01); A61K 31/506 (2006.01); A61P 25/16 (2006.01)

CPC A61K 31/439 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/4178 (2013.01); A61K 31/499 (2013.01); A61K 31/506 (2013.01); A61P 25/16 (2018.01)]

14 Claims

1. A method for treating a neurological disorder in a subject, the method comprising administering to the subject in need of such treatment a composition comprising a therapeutically effective amount of a CCR5 antagonist, wherein the CCR5 antagonist is maraviroc, aplaviroc, cenicriviroc or vicriviroc, wherein the neurological disorder is selected from the group consisting of Alzheimer's disease, dementia with Lewy bodies and multiple system atrophy.